Ovarian cancer risks may be lowered with aspirin
8 October 2018 | By European Pharmaceutical Review
A Harvard Chan School of Public Health study showed aspirin specifically in low doses could lower the risk of ovarian cancer...
List view / Grid view
Ovarian Cancer
Scientists identify cause of resistance to breast and ovarian cancer drug
10 May 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Scientists have identified a mutation that gives cancer cells resistance to the breakthrough cancer treatment olaparib and other PARP inhibitors...
Hemp shows potential for treating ovarian cancer
24 April 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers demonstrate hemp's ability to slow cancer growth and uncover mechanism for its cancer-fighting ability...
Ponatinib is found to be effective against SCCOHT
5 March 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Ponatinib is effective against SCCOHT, a type of ovarian cancer that mostly strikes young women and girls as young as 14 months...
FDA approves lynparza for breast cancer with BRCA gene mutation
15 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
The FDA has expanded the approved use of Lynparza to include the treatment of patients with metastatic breast cancer who have a BRCA gene mutation...
Merrimack initiates Phase 1 study of MM-310 in solid tumours
29 March 2017 | By Niamh Marriott, Junior Editor
Merrimack Pharmaceuticals have enrolled its first patient in a Phase 1 study of MM-310 in solid tumours.
Lynparza Phase III data demonstrates progression-free survival in ovarian cancer
17 March 2017 | By Niamh Marriott, Junior Editor
AstraZeneca’s Phase III SOLO-2 trial demonstrated a significant improvement in progression-free survival (PFS) in germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer patients treated with Lynparza (olaparib) tablets (300mg twice daily) compared with placebo in the maintenance setting. The trial met its primary endpoint of investigator assessed PFS (HR 0.30; 95%…
Phase III trial to evaluate avelumab as first-line treatment in ovarian cancer
6 July 2016 | By Victoria White, Digital Content Producer
Avelumab will be evaluated in combination with, and/or as follow-on treatment to, platinum-based chemotherapy in patients with epithelial ovarian cancer...
Aprea announces efficacy and safety data for APR-246 in ovarian cancer
7 June 2016 | By Victoria White, Digital Content Producer
Aprea presented clinical data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II trial of APR-246 at the ASCO annual meeting...
NICE says ‘yes’ to two ovarian cancer drugs, rejects three
27 April 2016 | By Victoria White, Digital Content Producer
The guidance recommends paclitaxel and PLDH for treating ovarian cancer that has returned after previous chemotherapy treatment...
TPIV 200 and durvalumab to be evaluated in a Phase II ovarian cancer study
22 April 2016 | By Victoria White, Digital Content Producer
TapImmune plans to initiate a Phase II trial of TPIV 200 in combination with AstraZeneca’s durvalumab in patients with platinum-resistant ovarian cancer...
ImmunoGen and Merck collaborate for ovarian cancer trial
5 February 2016 | By Victoria White
The companies are to are to assess ImmunoGen’s mirvetuximab soravtansine in combination with Merck’s Keytruda (pembrolizumab) in FRα-positive ovarian cancer...
FDA grants Fast Track Designation to TapImmune’s TPIV 200
3 February 2016 | By Victoria White
The FDA has granted the designation for maintenance therapy in subjects with platinum-sensitive advanced ovarian cancer...
FDA finally speeds up approval for ovarian cancer drugs
19 January 2016 | By Snehal Chougule, Allied Market Research
Snehal Chougule discusses the ovarian cancer treatment market and recent approvals by the US Food and Drug Administration...
Trial to investigate avelumab and entinostat in ovarian cancer
4 January 2016 | By Victoria White
Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody and entinostat is an investigational oral small molecule that targets immune regulatory cells...
Follow: